Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 801 results for "Tecfidera"

Will Bass's Patent Challenge Set Forward Pharma's Tecfidera Ro...

FWP), Includes: BIIB by: Markman Advisors Subscribers to SA PRO had an early look at this article. Learn more about PRO ยป Summary Recently filed Kyle Bass IPR presents an existential risk to Forward Pharma setting up a binary event. Neither ... Seeking Alpha, 1 week ago

27 images for Tecfidera

Monthly Prescribing Reference, 1 month ago
Motley Fool, 3 weeks ago
Jutia Group, 3 weeks ago
The Fiscal Times, 3 weeks ago
Triangle Business Journal, 3 weeks ago
Triangle Business Journal, 3 weeks ago
NewsReality.com, 3 weeks ago
NewsReality.com, 3 weeks ago
NewsReality.com, 3 weeks ago
NewsReality.com, 3 weeks ago
Irish Times

Biogen Inc Q1 Profits Miss Estimates On Slowing Growth In Tecfidera Sales

Biogen Inc ( NASDAQ:BIIB ) announced its first-quarter financial results for 2015 before the opening bell on Friday, reporting lower-than-expected growth in its quarterly revenue and profits on the back of slowing sales of its top-selling multiple ...
 Bidness Etc4 weeks ago UPDATE 2-Biogen reports slowing sales of Tecfidera, shares plunge  CNBC4 weeks ago Biogen results disappoint as Tecfidera sales slow  Irish Times4 weeks ago UPDATE 1-Biogen 1st qtr results disappoint Wall Street as Tecfidera sales slow  CNBC4 weeks ago
[x]  
4 Traders

Biogen Inc (BIIB) Stock Price Tumbles 8% After Sales Of Multiple Sclerosis Drug Tecfidera Miss Analyst Estimate In Q1

The share price of Biogen Inc. (NASDAQ:BIIB) tumbled as much as 8 percent, to $395, Friday after sales of the biotechnology company's multiple-sclerosis drug Tecfidera came in below the analysts' consensus estimate for the first quarter. With a ...
 Austin American Statesman4 weeks ago Biogen 1st qtr profit jumps 71 pct as MS drug Tecfidera shines  CNBC4 weeks ago Biogen sales, profit miss the mark as Tecfidera flags  FiercePharma4 weeks ago BIOGEN : first-quarter profit jumps 71 percent as MS drug Tecfidera shines  4 Traders4 weeks ago
[x]  

Biogen Drops as Profit Disappoints Amid Slow Tecfidera Sales

(Updates with closing share price in fifth paragraph.) Earnings excluding one-time items rose to $3.82 a share from $2.47 a year earlier. Analysts had forecast $3.88 on average, according to estimates compiled by Bloomberg. Revenue increased 20 ...
 Washington Post4 weeks ago Biogen Profit Trails Estimates as Tecfidera Growth Slows  Washington Post4 weeks ago
Monthly Prescribing Reference

Biogen announces encouraging data from multiple sclerosis studies

Biogen Inc., a biotechnology company, has announced encouraging data from studies with TECFIDERA as a long-term treatment for people who are living with relapsing forms of multiple sclerosis, or MS. Data show TECFIDERA significantly reduced relapses ...
 Individual.com3 weeks ago Meredith Vieira: Conversations on MS  EverydayHealth.com3 weeks ago Dimethyl fumarate (Tecfidera) longer-term effects  Multiple Sclerosis Trust1 month ago Biogen : Tecfidera Data Reinforce Efficacy For Newly-Diagnosed MS Patients  RTTNews.com1 month ago
[x]  

Biogen Q1 Misses Estimates As Tecfidera Stalls

B ig-cap biotech Biogen (NASDAQ: BIIB ) missed Wall Street's Q1 estimates Friday as its multiple-sclerosis drug Tecfidera ran into unexpected headwinds, sending its stock down to a two-month low in early trading. Biogen's earnings excluding ...
 Investor's Business Daily4 weeks ago Biogen's MS Drug Sales Light, Alzheimer's Data Pushed Back  Yahoo! Singapore4 weeks ago
[x]  

Biogen Misses on 1Q Earnings, Tecfidera Falls Short - Analyst Blog

Biotech company, Biogen BIIB, reported first quarter 2015 earnings per share of $3.82 (including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate of $3.91 but 55.9% above the year-ago earnings. Biogen Idec ...
 Yahoo! Finance4 weeks ago

Biogen's Weak Tecfidera Sales in 1Q Don't Affect Our Fair Value Estimate

We don't recognize that email. Please try again. Forgot Password? Password Please enter your password. The password you entered does not match our records. Please try again. Our records show you have a Morningstar account, but you are not ...
 Morningstar.com4 weeks ago

Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera

News Editor Hedge fund investor Kyle Bass, head of Dallas, TX-based Hayman Capital Management L.P., files a challenge to a key patent covering Biogen's (BIIB +0.6%) $2.9B Tecifera (dimethyl fumarate). Specifically, he is challenging the validity ...
 Seeking Alpha1 month ago Bass Challenges Patent on Biogen's Blockbuster Tecfidera  FINalternatives1 month ago Celgene, Shire Make Five as Kyle Bass Expands Drug Patent Fight  Bloomberg1 month ago
TheStreet.com

Biogen's first-quarter revenue up 20 percent, but misses estimates as Tecfidera sales fall short

Biogen's first-quarter sales climbed 20 percent year-over-year to $2.6 billion, boosted by increased revenue from multiple sclerosis drugs, including Tecfidera, although the figure missed analyst estimates of $2.7 billion, the company reported ...
 FirstWord Pharma4 weeks ago Biogen Reports First Quarter 2015 Revenues of $2.6 Billion  Reuters4 weeks ago BIOGEN : Reports First Quarter 2015 Revenues of $2.6 Billion  4 Traders4 weeks ago Forward Pharma Reports First Quarter 2015 Financial and Operational Results  Marketplace1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less